Binitio Biomedical’s Exia 160 and Exia 160XL now Available Through MediLumine

Binitio Biomedical Exia 160

One challenge for development of non toxic micro-CT contrast agents is to load a high concentration of an X-ray attenuating element in a nanoparticulate formulation with particle size distribution small enough to avoid accumulation in lungs but large enough to avoid kidney filtration.  Binitio Biomedical’s Exia 160 and Exia 160XL meet these requirements with sufficient stealth properties for vascular imaging. In addition, they are made of components which are metabolized by catabolic pathways in the body thus enabling metabolic imaging of the myocardium and brown adipose tissue.

Share This Post

More To Explore

Enhancing Cardiac Repair with ENPP1 Inhibition

A recent study offers insights into a novel approach to cardiac repair by inhibiting ENPP1, an enzyme critical to regulating extracellular nucleotide metabolism. MediLumine’s Fenestra

Managed by Carbon Digital